Ch. 56 Flashcards
metabolic syndrome is
the simultaneous presence of metabolic factors that increase the risk for Type 2 DM
metabolic syndrome includes
- abdominal obesity
- hyperglycemia
- hypertension
- hyperlipidemia
incidence and prevalence of DM
- more than 34 million people in the US are living with DM
- 7.3 million in US are undiagnosed
- 86 million in the US with prediabetes
- 2.2 million adults in Canada
health promotion and maintenance of DM
- control of DM and its complications is the major focus of health promotion activities
- low-calorie diet
- increase acitivity
Type 1 DM
- beta cell destruction = absolute insulin deficiency
- autoimmune
- idiopathic
- not controlled by diet
- ONLY treated by insulin
Type 2 DM
- insulin resistance to insulin deficiency
- later onset
- risk factors can be mitigated
- can be treated w/ insulin, diet, exercise, mult. treatment options
ethnic disparities in DM in the US
African Americans: 12.6%
Hispanics: 11.8%
Asian Americans: 8.4%
Non-Hispanic Whites: 7.1%
American Indians in Southern AZ: 24.1%
DM assessment: risk factors
- decreased PA
- obesity/high BMI
- poor diet
- genetics/ fam history
DM assessment: s/sx
- always tired
- frequent urination
- sudden weight loss
- wounds that won’t heal
- sexual problems
- vaginal infections (yeast)
- always thirsty
- numb or tingling hands or feet
- blurry vision
- always hungry
DM assessment: labs/screenings
- glycosylated hemoglobin (A1c)
- FBG
Hgb A1c levels
healthy: < 5.3
trending 5.3-5.5
prediabetic: 5.6-6.4
diabetic: > 6.4
lifespan of Hgb: 3 months
patient problems related to DM
- potential for injury
- potential for poor wound healing
- potential for kidney disease (damage to blood vessels causes kidneys to not function properly)
- potential for complications
nursing actions with DM
- preventing injury from hyperglycemia
- enhancing surgical recovery
- preventing injury from peripheral neuropathy
- reducing risk for kidney disease
- preventing complications
PO medication for DM
- sulfonylurea agents: glipizide, glyburide, glimepiride
- meglitinide analogues: repaglinide
- biguanides: metformin
- thiazolidinediones: pioglitazone, rosiglitazone
- DPP-4 inhibitors: sitagliptin (januvia)
insulin therapy: types of insulin
- rapid: aspart, lispro, humalog
- short: regular, humalin
- intermediate: NPH
- long: glargine/lantus
mixing insulin
- make sure that they can be mixed/compatible
- regular and NPH: clear before cloudy (R before N)
- inject air into NPH, then inject air in R, draw up R, then draw up NPH
factors that influence insulin absorption
- fat scarring
- injection site (abdomen is fastest site)
- high temperature (hot shower, bath, water bottle, spa, sauna)
- massaging/vigorously rubbing injection site
**(heat increases, cold decreases absorption)
rapid-acting insulin
aspart, lispro, humaLOG
- onset: 10-20 min
- peak: 1-3 hours
- duration: 3-5 hours
- take with meals?: want food tray in the room
short-acting insulin
regular (given IV route only), humaLIN
- onset: 30-60 min
- peak: 1-5 hours
- duration: 6-10 hours
- take with meals?: 30 mins before each meal
intermediate-acting insulin
NPH
- onset: 60-120 min
- peak: 6-14 hours
- duration: 16-24 hours
- take with meals?: 30-45 mins before meals
long-acting insulin
glargine (lantus)
- onset: 70 min
- peak: none
- duration: 18-24 hours
- take with meals?: same time every day, usually within 1 hour of breakfast
health teaching of DM
- normal values
- Hgb A1c
- how to take a glucose finger stick?
- exercise: promotes uptake of glucose without insulin, also to decrease weight
- prevent complications: peripheral neuropathy